Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age

Abstract

Both MenACWY vaccines safely induced protective sustained antibody responses against all targeted serogroups in MCC-primed teenagers.

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

“…A MenACWY-TT booster dose administered 10 y after primary vaccination resulted in robust immunologic responses in all subjects, regardless of meningococcal vaccine used for primary immunization. Consistent with studies showing robust immunologic responses to MenACWY booster doses in adolescents primed with a MenC vaccine at preschool age, 17,18 these findings suggest that a booster dose of MenACWY-TT might be a suitable option for adolescents who previously received a MenC-CRM, MenACWY-PS, or MenACWY-TT vaccine in early childhood.…”

Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study

“…39 We presume that acceptance or uptake of MenACWY vaccination will be similar to that of the MenC vaccine, because the vaccines are very similar with respect to immunogenicity, safety, and targeted disease. 40,41 We noted some important differences in the progress of the outbreaks of meningococcal serogroup W disease between England and the Netherlands. For example, in England, cases of serogroup W disease appeared to increase more gradually over time (with cases eventually doubling in more recent years) than in the Netherlands, where the incidence increased by five times within 1 year, albeit with small numbers of cases.…”

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

“…Functional antibodies against each vaccine serogroup were measured by a serum bactericidal assay using human complement (hSBA) in all but two studies which used a baby rabbit complement source [22,23], and one study where the method was not specified [24]. Historically, an hSBA assay cutoff dilution of 1:4 is considered a surrogate end point indicating clinical protection against MenC [25].…”

“…Studies in adolescents primed with diverse meningococcal vaccines, including MenACWY-CRM, MenACWY-DT, MenC-TT, MenC-CRM, or quadrivalent meningococcal polysaccharide vaccines, show that a MenACWY-CRM booster can induce hSBA titers ≥1:8 in almost all subjects. The booster response indicates successful induction of an anamnestic immune response irrespective of the vaccine used for priming [24,47,49].…”